Compare Stocks: ELOX, AMRN, TTRX, and NMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.92 +0.3%	$14.59	$12.96 ▼ $20.90	$293.99M	0.81	78,436 shs	30,521 shs
ELOX Eloxx Pharmaceuticals	$15.49 -7.6%	$14.76	$8.20 ▼ $23.40	$62.52M	-1863.11	55,575 shs	31,942 shs
NMRA Neumora Therapeutics	$1.35 +1.1%	$1.61	$0.83 ▼ $3.65	$252.73M	2.75	1.68 million shs	309,532 shs
TTRX Turn Therapeutics	$10.15 +5.7%	$8.90	$2.57 ▼ $26.50	$302.35M	N/A	50,645 shs	31,095 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	-0.64%	+0.29%	-2.66%	-4.08%	-7.71%
ELOX Eloxx Pharmaceuticals	+11.28%	-16.11%	-3.79%	-62.54%	+138,495.04%
NMRA Neumora Therapeutics	-4.32%	-12.79%	-17.39%	-24.00%	-23.12%
TTRX Turn Therapeutics	-2.44%	-0.83%	+14.83%	+49.53%	+959,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRN Amarin	$13.92 +0.3%	$14.59	$12.96 ▼ $20.90	$293.99M	0.81	78,436 shs	30,521 shs
ELOX Eloxx Pharmaceuticals	$15.49 -7.6%	$14.76	$8.20 ▼ $23.40	$62.52M	-1863.11	55,575 shs	31,942 shs
NMRA Neumora Therapeutics	$1.35 +1.1%	$1.61	$0.83 ▼ $3.65	$252.73M	2.75	1.68 million shs	309,532 shs
TTRX Turn Therapeutics	$10.15 +5.7%	$8.90	$2.57 ▼ $26.50	$302.35M	N/A	50,645 shs	31,095 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRN Amarin	-0.64%	+0.29%	-2.66%	-4.08%	-7.71%
ELOX Eloxx Pharmaceuticals	+11.28%	-16.11%	-3.79%	-62.54%	+138,495.04%
NMRA Neumora Therapeutics	-4.32%	-12.79%	-17.39%	-24.00%	-23.12%
TTRX Turn Therapeutics	-2.44%	-0.83%	+14.83%	+49.53%	+959,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRN Amarin	1.33	Sell	$13.00	-6.61% Downside
ELOX Eloxx Pharmaceuticals	2.75	Moderate Buy	$41.50	167.91% Upside
NMRA Neumora Therapeutics	2.60	Moderate Buy	$6.57	388.58% Upside
TTRX Turn Therapeutics	2.50	Moderate Buy	$8.00	-21.18% Downside

Current Analyst Ratings Breakdown

Latest ELOX, AMRN, TTRX, and NMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/20/2026	ELOX Eloxx Pharmaceuticals	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	TTRX Turn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2026	ELOX Eloxx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	NMRA Neumora Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/22/2026	ELOX Eloxx Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$40.00
7/21/2026	TTRX Turn Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRN Amarin	$213.65M	1.38	$0.36 per share	38.70	$22.07 per share	0.63
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	($85.17) per share	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.62 per share	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	$0.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)
TTRX Turn Therapeutics	-$3.19M	-$0.29	N/A	N/A	N/A	N/A	-230.84%	-53.19%	N/A

Latest ELOX, AMRN, TTRX, and NMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/12/2026	Q2 2026	TTRX Turn Therapeutics	N/A	-$0.20	N/A	-$0.20	N/A	N/A
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
TTRX Turn Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRN Amarin	N/A	3.67	2.67
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
NMRA Neumora Therapeutics	1.19	4.50	4.50
TTRX Turn Therapeutics	8.83	1.19	1.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRN Amarin	22.25%
ELOX Eloxx Pharmaceuticals	2.90%
NMRA Neumora Therapeutics	47.65%
TTRX Turn Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AMRN Amarin	4.21%
ELOX Eloxx Pharmaceuticals	25.90%
NMRA Neumora Therapeutics	26.94%
TTRX Turn Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRN Amarin	360	21.12 million	20.23 million	Optionable
ELOX Eloxx Pharmaceuticals	N/A	4.04 million	2.99 million	N/A
NMRA Neumora Therapeutics	108	187.90 million	137.28 million	Optionable
TTRX Turn Therapeutics	2	29.79 million	N/A	N/A

ELOX, AMRN, TTRX, and NMRA Headlines

Recent News About These Companies

Ieq Capital LLC Makes New Investment in Turn Therapeutics Inc. $TTRX

August 26, 2026 | marketbeat.com

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

August 20, 2026 | finance.yahoo.com

Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance

August 18, 2026 | tipranks.com

Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5% - Time to Sell?

August 13, 2026 | marketbeat.com

Turn Therapeutics Inc. GAAP EPS of -$0.20

August 13, 2026 | seekingalpha.com

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

August 12, 2026 | businesswire.com

Turn Therapeutics Inc. Share Price (TTRX.US)

August 5, 2026 | lse.co.uk

Turn Therapeutics Inc.

August 2, 2026 | cnn.com

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

July 28, 2026 | businesswire.com

Turn Therapeutics Inc. (TTRX)

July 11, 2026 | sg.finance.yahoo.com

Why Is Turn Therapeutics Stock Trading Higher Today?

July 7, 2026 | benzinga.com

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

July 7, 2026 | businesswire.com

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

July 6, 2026 | businesswire.com

Turn Therapeutics Stock Short Interest Report | NASDAQ:TTRX | Benzinga

July 3, 2026 | benzinga.com

Turn Therapeutics appoints veteran executive to board

July 3, 2026 | theglobeandmail.com

TTRX Turn Therapeutics Inc.

June 19, 2026 | seekingalpha.com

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

June 1, 2026 | businesswire.com

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

May 27, 2026 | businesswire.com

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

May 19, 2026 | businesswire.com

Turn Therapeutics Appoints Former FDA Chief to Lead GX-03

May 18, 2026 | tipranks.com

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

May 18, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, AMRN, TTRX, and NMRA Company Descriptions

Amarin NASDAQ:AMRN

$13.92 +0.04 (+0.29%)

As of 02:53 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Eloxx Pharmaceuticals NASDAQ:ELOX

$15.49 -1.28 (-7.63%)

As of 02:52 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Neumora Therapeutics NASDAQ:NMRA

$1.34 +0.02 (+1.13%)

As of 03:01 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Turn Therapeutics NASDAQ:TTRX

$10.15 +0.55 (+5.73%)

As of 02:58 PM Eastern

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, AMRN, TTRX, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, AMRN, TTRX, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, AMRN, TTRX, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, AMRN, TTRX, and NMRA Company Descriptions

Amarin NASDAQ:AMRN

Eloxx Pharmaceuticals NASDAQ:ELOX

Neumora Therapeutics NASDAQ:NMRA

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, AMRN, TTRX, and NMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, AMRN, TTRX, and NMRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, AMRN, TTRX, and NMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, AMRN, TTRX, and NMRA Company Descriptions

Amarin NASDAQ:AMRN

Eloxx Pharmaceuticals NASDAQ:ELOX

Neumora Therapeutics NASDAQ:NMRA

Turn Therapeutics NASDAQ:TTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools